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A novel biomarker panel for 
irritable bowel syndrome and 
the application in the general 
population
Zlatan Mujagic1,2,*, Ettje F. Tigchelaar1,3,*, Alexandra Zhernakova1,3, Thomas Ludwig1,4, 
Javier Ramiro-Garcia1,5, Agnieszka Baranska1,6, Morris A. Swertz1,3, Ad A. M. Masclee2, 
Cisca Wijmenga1,3, Frederik J. van Schooten6, Agnieszka Smolinska1,6,† & 
Daisy M. A. E. Jonkers1,2,†
Biological markers that measure gut health and diagnose functional gastro-intestinal (GI) disorders, 
such as irritable bowel syndrome (IBS), are lacking. The objective was to identify and validate a 
biomarker panel associated with the pathophysiology of IBS that discriminates IBS from healthy 
controls (HC), and correlates with GI symptom severity. In a case-control design, various plasma and 
fecal markers were measured in a cohort of 196 clinical IBS patients and 160 HC without GI symptoms. A 
combination of biomarkers, which best discriminates between IBS and HC was identified and validated 
in an independent internal validation set and by permutation testing. The correlation between the 
biomarker panel and GI symptom severity was tested in IBS patients and in a general population 
cohort of 958 subjects. A set of 8 biomarker panel was identified to discriminate IBS from HC with high 
sensitivity (88.1%) and specificity (86.5%). The results for the IBS subtypes were comparable. Moreover, 
a moderate correlation was found between the biomarker panel and GI symptom scores in the IBS 
(r = 0.59, p < 0.001) and the general population cohorts (r = 0.51, p = 0.003). A novel multi-domain 
biomarker panel has been identified and validated, which correlated moderately to GI symptom severity 
in IBS and general population subjects.
Interest in ‘gut health’ is rapidly emerging1. Gastrointestinal (GI) symptoms and disorders occur frequently in the 
general population and may reflect compromised gut health2. Although gut health is difficult to define, five major 
domains related to a healthy GI system have been proposed by Bischoff. These domains include effective digestion 
and absorption, normal and stable microbiota, effective immune status, absence of GI illness and status of general 
well-being1. As various underlying mechanisms may affect these domains, it is challenging to identify and vali-
date markers for gut health. This is particularly relevant when healthy subjects are compared with subjects with 
functional GI disorders, or when evaluating potential benefits of dietary interventions in the general population. 
For organic GI diseases, diagnostic tools and markers are generally available in daily clinical practice, such as GI 
endoscopy, histological examination of tissue samples or biomarkers (e.g. anti-transglutaminase antibodies)3,4. 
However, objective biological markers that aid the diagnostic process and facilitate follow up and assessment of 
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treatment efficacy of functional GI disorders, such as Irritable Bowel Syndrome (IBS), are lacking. Neither are 
markers available that correlate well with GI symptom severity5,6.
The Rome III symptom criteria are the current gold standard for the diagnosis of IBS. Although the Rome 
committee emphasizes that IBS is not a diagnosis of exclusion and should be based on symptom criteria, in 
daily clinical practice endoscopy, CT or ultrasound imaging, blood, fecal or other analyses are frequently used to 
exclude organic disorders7. Therefore, there is increasing interest in reliable biomarkers that can aid the diagnosis 
of IBS8,9. A clinically and scientifically relevant biomarker for IBS should be able to a) discriminate IBS patients 
from healthy subjects, b) discriminate IBS patients from subjects with organic GI disorders, and c) correlate with 
severity of GI symptoms, to be useful for monitoring of treatment efficacy. Finding objective biomarkers that cor-
relate with the severity of GI symptoms in IBS is also an important step towards suitable biomarkers for functional 
GI complaints and gut health in the general population.
Up to now, use of non-invasive single biomarkers for IBS has led to only moderate results5,6. Therefore, recent 
studies focused on biomarker panels9. To date, a specificity and sensitivity of 88% and 50%, respectively, has been 
reported for a 10 item-serum marker panel10, and of 64% and 81%, respectively, for a 34 item-serum/genetic 
marker panel for the discrimination of IBS patients versus healthy controls11. Though promising, biomarkers with 
higher predictive values are needed for daily clinical practice and scientific research. We postulated that com-
bining markers that reflect the multifactorial pathophysiology of IBS may lead to better results. Strong evidence 
exists for a combination of rather subtle pathophysiological changes, such as low-grade mucosal and systemic 
immune activation, intestinal barrier dysfunction, dysregulation in neural and neuro-hormonal signaling and 
altered microbiota and host-microbe interaction, that contribute to symptom generation in IBS12. These mecha-
nisms do overlap with the domains of gut health as described by Bischoff1.
In the current study, we hypothesized that biomarkers related to several domains of gut health and associ-
ated with the pathophysiology of IBS, can be combined and used as a highly sensitive and specific biomarker 
panel to discriminate clinically diagnosed IBS patients form healthy controls. Secondly, we hypothesized that 
this biomarker panel correlates with GI symptom severity, not only in IBS patients derived from a clinical setting 
with relatively high symptom burden, but also in subjects with mild to moderate GI symptoms from the general 
population.
The primary objective of the present study was to assess levels of selected plasma and fecal biomarkers, related 
to several domains of gut health, and to identify and validate a non-invasive biomarker panel, which best dis-
criminates IBS patients from healthy controls. The secondary objective was to correlate the biomarker panel to GI 
symptom severity in clinical IBS patients as well as in a large general population cohort.
Methods
In a case control design, two large Dutch cohorts were used, i.e. a clinical cohort of IBS patients and healthy con-
trols without GI symptoms (Maastricht IBS (MIBS) cohort)4,13, and a general population cohort (LifeLines (LL) 
DEEP)14. From both cohorts, subjects were included in the analyses if fecal and plasma samples and completed 
GI symptom scores were available. Identification and validation of the biomarker panel was conducted in clinical 
IBS patients and healthy controls of the MIBS cohort. The correlation of the biomarker panel to GI symptoms was 
evaluated in both cohorts.
Study participants; MIBS cohort. IBS patients, between 18 and 75 years of age, diagnosed by their treating 
physician and fulfilling Rome III criteria, were recruited via the outpatient gastroenterology-hepatology clinic of 
MUMC+ , a secondary and tertiary referral center, and via general practitioners in the area of Maastricht. Medical 
history was taken and GI endoscopy with biopsies, abdominal imaging and/or blood, breath and fecal analyses 
were performed to exclude organic disease, when indicated. Patients with a history of abdominal surgery, apart 
from appendectomy, laparoscopic cholecystectomy and hysterectomy, were excluded. Patients were assigned to 
IBS subtypes based on predominant bowel habits according to the Rome III criteria: diarrhea (IBS-D), consti-
pation (IBS-C), mixed stool pattern (IBS-M) and unspecified subtype (IBS-U). Age and sex matched healthy 
controls (HC) were enrolled via public advertising. A brief medical history was taken to exclude the presence of 
previous or current GI disorders or complaints. All study participants completed questionnaires regarding demo-
graphic characteristics and lifestyle factors. A 14-day end-of-day GI symptom diary was completed, addressing 
symptoms of abdominal discomfort and pain, nausea, bloating, belching, flatulence, diarrhea and constipation, 
on a 1-to-5 point Likert scale4.
Study participants; LL DEEP cohort. Study participants above 18 years of age and regardless of their 
medical background or current complaints were randomly enrolled from a large general population cohort in the 
Netherlands, i.e. LifeLines15. In a subgroup of the cohort, referred to as LifeLines Detailed Extensive Examination 
of Participants (LL DEEP), among others fecal and plasma samples were available and subjects completed 
self-report questionnaires on demographics and lifestyle factors, as well as a 7-day GI symptom diary, which was 
identical to the 14-day diary used in the MIBS cohort14. Information on clinical diagnoses of IBS was not available 
for this general population cohort.
All study participants gave written informed consent prior to inclusion. Study protocols were approved by the 
Maastricht University Medical Center+ (MUMC+ ) and University Medical Centre Groningen (UMCG) Ethics 
Committees, respectively, and were in compliance with the revised Declaration of Helsinki (64th WMA General 
Assembly, Fortaleza, Brazil, 2013). The MIBS cohort was registered in the US National Library of Medicine 
(http://www.clinicaltrials.gov, NCT00775060).
Selection of biomarkers. Forty-three potential biomarkers were selected based on extensive liter-
ature search, using the following selection criteria: i) markers are related to one or more gut health domains 
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as described by Bischoff1; ii) they potentially discriminate between subjects with healthy gut function and IBS 
patients; and iii) can be measured in blood or fecal samples collected according to generally accepted and appli-
cable procedures for bio sample collection. Based on expert panels, focusing on relevance and feasibility of the 
markers, fifteen biomarkers were selected to be measured (in both cohorts). Plasma citrulline, a marker of func-
tional enterocyte mass of the small bowel, was selected as indicator of the absorptive16,17 and barrier function of 
the small intestine18,19. Non-stimulated plasma cytokine levels, i.e. IL-1β , IL-6, IL-8, IL-10, IL-12p70 and TNF-α , 
were selected as markers of systemic immune activation20,21. Fecal calprotectin, a calcium and zinc-binding pro-
tein, was selected as an indicator of intestinal inflammation, proportional to neutrophil migration towards the 
intestinal tract22,23. Fecal human β-defensin 2 (HBD2), a human antimicrobial peptide produced by among others 
intestinal epithelial cells in response to (pathogenic) bacteria, was selected as an indicator of host defense against 
microbes24,25. Fecal short chain fatty acids (SCFAs), i.e. acetate, propionate, butyrate, valerate, and caproate, are 
products of microbial fermentation of non-digested oligosaccharides in the colon, and were selected as indicators 
of gut intraluminal metabolic activity. SCFAs have been associated to multiple pathological and physiological 
mechanisms in humans, e.g. modulation of inflammation, satiety, carcinogenesis, and are an important energy 
source for colonocytes26,27. Fecal chromogranin A (CgA), was selected as an indicator of the intestinal neuroendo-
crine cell activity. This peptide is produced by among others enterochromaffin cells, and is co-localized in storage 
granules with serotonin23,28–30.
Measurement of biomarkers. Fecal and blood samples were collected using standardized collection pro-
cedures. Venous blood was collected in K2EDTA (BD Vacutainer® ) tubes and centrifuged to obtained plasma 
supernatants, which were aliquoted and frozen at − 80 °C until analysis. In the same time period, subjects col-
lected stool samples, which were aliquoted and stored at − 80 °C within 24 hours after defecation. All markers 
were measured simultaneously to avoid additional thaw cycles, by ‘Medische Laboratoria Dr. Stein & Colleges’, 
The Netherlands. Calprotectin and HBD2 were assessed using a commercial enzyme-linked immunosorbent 
assay (ELISA, by Bühlmann Laboratories, Switzerland, and Immunodiagnostik AG, Germany, respectively)23,25, 
and CgA using a commercial radioimmunoassay (RIA, Euro-Diagnostica, Sweden)23, as described previously23,25. 
Fecal SCFAs, i.e. acetate, propionate, butyrate, valerate and caproate, were measured by gas chromatography-mass 
spectrometry (GC-MS) according to the method described by Garciá-Villalba et al.31. Concentrations of 
plasma citrulline were determined by high pressure liquid chromatography (HPLC) fluorescence detection, as 
described previously16. Plasma cytokines, i.e. IL-1β , IL-6, IL-8, IL-10, IL-12p70 and TNF-α , were measured by 
ProcartaPlexTM multiplex immunoassay (eBioscience, USA), as described previously32,33.
Data and statistical analysis. Levels of individual biomarkers were compared between groups using the 
Mann-Whitney U test, due to left skewed distributions, with post-hoc correction for multiple testing by the 
Benjamini–Hochberg step-up procedure34. The method of multiple imputations was implemented as part of the 
statistical procedure for biomarker levels that were below the detection limit35. These were randomly (with uni-
form distribution) replaced by levels ranging from zero till limit of detection. The assignment of values below 
detection limit was repeated 2000 times. All statistical results were calculated as average values over the 2000 
iterations.
The data set of the MIBS cohort was then used for identification and validation of a biomarker panel that best 
discriminates between IBS and HC, using a supervised technique, namely Partial Least Square Discriminant 
Analysis (PLS-DA)36. This strategy for supervised data analysis via PLS-DA involved a random division of the 
MIBS cohort into a representative training set (80% of samples per group) and a validation set (20% of sam-
ples per group), as described by Guyon37. Within the training set we applied double cross-validation procedure 
for model optimization, the most discriminatory biomarker selection and for development of the final PLS-DA 
classification model38. The latter was done in the independent validation set of the MIBS cohort (the randomly 
separated 20% of samples not used in any optimization steps), by testing the performance of selected biomarker 
panel to classify individuals as being an IBS patient or HC.
Note, that commonly used cross-validation leads to optimistic bias (i.e. too low error estimate)39. Thus, it was 
not used in our analyses for evaluating the predictive power of the PLS-DA model.
Furthermore, linear correlations between the most discriminatory biomarker panel and a set of GI symptoms, 
including all items of the GI symptom diary were tested in the MIBS and in the general population LL DEEP 
cohort, using canonical correlation analysis (CCA)40, which is an extension of bi-variate correlation. CCA calcu-
lates a linear correlation that best explains the variability both within and between the biomarker panel and the 
measured GI symptoms.
Results
Identification and validation of the most discriminative biomarker panel for IBS versus HC. 
Baseline characteristics for 196 clinical IBS patients and 160 age and gender matched HC without GI symptoms 
(MIBS cohort) are presented in Table 1. All GI symptom scores were higher in IBS patients compared to HC. The 
scores for constipation and diarrhea were significantly altered, in line with the IBS subtypes (data not shown).
The biomarker data for IBS and HC subjects of the total MIBS cohort are presented in Table 2. Based on uni-
variate comparisons, non-stimulated IL-1β and IL-6 were significantly lower, while IL-12p70 was significantly 
higher in plasma samples of IBS patients relative to HC. In fecal samples, CgA and calprotectin were significantly 
increased, while HBD2, and the SCFAs, valerate and caproate, were significantly decreased in IBS patients com-
pared to HC. These differences remained statistically significant after correction for multiple testing.
For identification of the most discriminative biomarker panel, the MIBS training cohort was used. A final 
panel of 8 biomarkers, i.e. IL-1β , IL-6, IL12p70, TNF-α , CgA, HBD2, calprotectin and caproate, was identified 
with PLS-DA to have the best predictive value for the IBS versus HC group. This panel is presented in Fig. 1, 
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wherein the regression coefficient level indicates the relative importance of the specific marker within the bio-
marker panel. Markers with a positive regression coefficient are decreased in the IBS group, and vice versa. The 
regression coefficients and the biomarker concentrations were used to calculate a total score for the biomarker 
panel per subject. This was done by multiplying the concentration of each biomarker as actually measured, by the 
level of importance of that specific marker within the panel obtained from the regression coefficient. The total 
score represents the probability of being IBS or HC. The values of these scores were found to be significantly dif-
ferent between the IBS versus the HC group in the validation set, as shown in Fig. 2 (p < 0.001).
Thereafter, the pre-assigned independent validation set of IBS patients and HC of the MIBS cohort that were 
left out of the biomarker panel discovery step, was used to test the performance of the biomarker panel for the 
discrimination between IBS patients and HC. This is illustrated by the receiver operating characteristic (ROC) 
curve in Fig. 3, with an area under the curve (AUC) of 0.89. The line of the ROC curve represents the sensitivity 
and specificity of the classification model, which is derived from an algorithm representing all 8 biomarkers in 
the panel. The sensitivity and specificity at the optimal threshold for the diagnosis of IBS were 88.1% and 86.5%, 
respectively, and the positive and negative predictive values were 94.4% and 74.0%, respectively.
Parameter IBS (n = 196) HC (n = 160)
Demographics and Lifestyle
 Age (mean years ± SD) 44.8 ± 16.4 43.9 ± 19.2
 Female sex (%) 70.4 61.3
 BMI (mean kg/m2 ± SD) 25.0 ± 4.6* 24.0 ± 3.9
 Duration of IBS symptoms (mean years ± SD) 13.6 ± 10.8 –
 IBS subtype: IBS-D/IBS-C/IBS-M/IBS-U (n) 71/34/78/13 –
 Current or previous smoker (%) 51.6*** 39.3
 Alcohol abstainers: 0 units/week (%) 42.1*** 19.1
 Moderate alcohol use: 1–15 units/week (%) 54.7** 70.7
GI symptoms assessed by end-of-day diary, 14-day mean ± SD
 Abdominal pain 2.3 ± 0.9*** 1.1 ± 0.2
 Abdominal discomfort 2.4 ± 0.8*** 1.1 ± 0.2
 Bloating 2.2 ± 0.9*** 1.1 ± 0.2
 Belching 1.6 ± 0.7*** 1.1 ± 0.3
 Nausea 1.6 ± 0.8*** 1.0 ± 0.1
 Flatulence 2.3 ± 0.9*** 1.3 ± 0.5
 Constipation 1.5 ± 0.7*** 1.1 ± 0.2
 Diarrhea 1.5 ± 0.6*** 1.0 ± 0.1
Table 1.  Baseline characteristics of the MIBS cohort groups (i.e. IBS patients versus HC). Differences tested 
with independent samples t-test and Pearson Chi2; *p < 0.05; **p < 0.01; ***p < 0.001 vs. HC.
Plasma biomarkers (median [Q1; Q3]) IBS (n = 196) HC (n = 160) p-value
Citrulline (μ mol/l) 41.9 [33.9; 50.5] 39.3 [33.0; 47.2] NS
IL-1β (μ g/l) 0.15 [0.08; 0.71] 0.19 [0.10; 1.46] 0.01
IL-6 (μ g/l) 0.24 [0.12; 0.36] 0.52 [0.20; 3.13] < 0.001
IL-8 (μ g/l) 1.69 [0.95; 2.52] 1.60 [1.14; 2.45] NS
IL-10 (μ g/l) 0.86 [0.69; 1.09] 0.84 [0.61; 1.04] NS
IL-12p70 (μ g/l) 2.19 [1.21; 2.99] 1.20 [0.11; 2.00] < 0.001
TNF-α (μ g/l) 0.14 [0.07; 3.20] 0.13 [0.06; 1.53] NS
Fecal biomarkers (median [Q1; Q3])
 Chromogranin A (CgA) (nmol/g) 15.2 [7.6; 45.8] 9.4 [6.3; 27.3] 0.001
 Calprotectin (μ g/g) 37.3 [18.7; 73.5] 21.6 [6.8; 47.8] < 0.001
 Human β-defensin 2 (HBD2) (ng/g) 31.3 [18.8; 51.9] 38.4 [27.1; 60.5] < 0.01
 SCFA (C2): Acetate (μ mol/g) 33.4 [22.5; 47.1] 35.7 [25.9; 47.4] NS
 SCFA (C3): Propionate (μ mol/g) 9.5 [6.8; 14.0] 9.5 [6.6; 13.8] NS
 SCFA (C4): Butyrate (μ mol/g) 7.8 [4.6; 13.2] 9.4 [5.9; 13.5] NS
 SCFA (C5): Valerate (μ mol/g) 1.2 [0.8; 1.8] 1.5 [1.0; 2.1] 0.01
 SCFA (C6): Caproate (μ mol/g) 0.1 [0.0; 0.5] 0.3 [0.1; 0.9] < 0.001
Table 2.  Levels of biomarkers of the MIBS cohort (i.e. IBS patients versus HC). Difference tested with 
Mann Whitney U test (presented p-value). Statistically significant differences did not diminish after post-hoc 
correction for multiple testing by Benjamini–Hochberg step up procedure.
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The results for the three largest IBS subtypes, for the set of 8 biomarkers, were comparable to the total IBS 
group, i.e. area under ROC curve of 0.86 for IBS-D, 0.80 for IBS-C and 0.89 for IBS-M in comparison to HC. 
These results were obtained by stratifying the number of individuals of each subtype in the validation set. Due to 
a small sample size in the IBS-U subtype (n = 13), the AUC was not calculated for this subtype.
In a post hoc analysis, we calculated the likelihood ratio, i.e. the proportion of IBS subjects with a positive test 
divided by the proportion of control subjects with a positive test by the biomarker panel. We are mostly interested 
in positive likelihood ratio since it tells the clinical concept of ruling-in disease. The negative likelihood ratio 
corresponds to the clinical conception of ruling-out disease. The positive likelihood ratio is equal to 6.5 and it was 
calculated as the ratio between the sensitivity and 100-specificity. The negative likelihood ratio of the biomarker 
panel is equal to 0.14 and it was calculated as the ratio between 100-sensitivity and specificity.
Correlation between the biomarker panel and GI symptoms in the MIBS cohort. In the total 
MIBS cohort (i.e. 160 HC and 196 IBS patients), the strongest correlation, i.e. correlation coefficient of 0.59 
(p < 0.001), was found between the 8-item biomarker panel (Fig. 1) and a set of GI symptoms, involving the 
following symptom scores: 14-day mean scores of abdominal pain, abdominal discomfort, bloating, flatulence 
and nausea. No correlations were found between the biomarker panel and the other GI symptoms assessed by the 
diary, i.e. belching, constipation and diarrhea.
Figure 1. The final 8-item biomarker panel. The length of the bar, i.e. positive or negative regression 
coefficient level, indicates the relative importance of the specific marker within the biomarker panel. Positive 
markers are decreased in IBS patients compared to HC, and vice versa for the negative markers.
Figure 2. Box plot representing the total score obtained for the 8-item biomarker panel for the IBS and 
HC group. The total score was obtained by multiplying the real concentration of measured biomarkers in the 
validation set by the regression coefficient per marker (Fig. 1). It represents the probability of being IBS or HC.
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Application of the biomarker panel in the general population LL DEEP cohort. The potency of 
the biomarker set in the general population was evaluated by investigating the correlation between the 8-item 
biomarker panel (Fig. 1) and GI symptoms assessed by the 7-day end-of-day GI symptom diary for the LL DEEP 
cohort (Tables 3 and 4). Since GI symptom severity scores in the total cohort (n = 958) were low, only subjects 
from the LL DEEP cohort with a GI symptom diary 7-day mean score for abdominal pain and discomfort of 1.5 
or higher were included in the correlation analysis. This cut-off value indicates the subject had at least 2 days with 
moderately-severe or 4 days with slightly-severe GI symptoms during those 7 days. The cut-of value was further 
supported by data of the MIBS cohort in which 95% of healthy controls had end-of-day diary mean-scores below 
1.5 for these GI symptoms. A GI symptom diary mean score of 1.5 or higher was found in 221 (23%) participants 
of the LL DEEP cohort. In this LL DEEP subgroup, the 8-item biomarker panel was found to correlate signifi-
cantly with a set of GI symptoms, i.e. 7-day mean scores of abdominal pain, discomfort, constipation, belching 
and nausea, resulting in a correlation coefficient of 0.51 (p = 0.003).
Discussion
In the current study, we investigated a combination of markers related to several gut health domains and iden-
tified and validated a novel non-invasive biomarker panel, with a high predictive value (area under ROC curve 
of 0.89) for the discrimination between clinically diagnosed IBS patients who fulfilled the Rome III criteria and 
healthy controls who did not have any GI complaints. The 8-item biomarker panel correlated moderately (r = 0.59, 
p < 0.001) to GI symptom severity in the IBS cohort and the general population cohort (r = 0.51, p = 0.003).
Figure 3. ROC curve, with an area under the curve (AUC) of 0.89 for the discrimination between IBS 
patients and HC in the validation set, using the final 8-item biomarker panel. 
Parameters of general population subjects n = 958
Demographics and Lifestyle
 Age (mean years ± SD) 45.2 ± 13.2
 Female sex (%) 58.5
 BMI (mean kg/m2 ± SD) 25.5 ± 4.5
 Current smokers (%) 18.9
GI symptoms assessed by end-of-day diary, 7-day mean ± SD
 Abdominal pain 1.2 ± 0.4
 Abdominal discomfort 1.3 ± 0.5
 Bloating 1.4 ± 0.5
 Belching 1.1 ± 0.3
 Nausea 1.1 ± 0.3
 Flatulence 1.6 ± 0.6
 Constipation 1.1 ± 0.4
 Diarrhea 1.1 ± 0.3
Table 3.  Baseline characteristics of the LL DEEP cohort: general population.
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In the search for a non-invasive biomarker panel for IBS, we measured 15 biomarkers in a large group of study 
participants. Eight markers, i.e. plasma IL-1β , IL-6, IL-12p70, and fecal CgA, calprotectin, HBD2, valerate, and 
caproate, proved to be significantly altered in IBS patients compared to HC, when tested by univariate analyses 
(Table 2). Of the 8 markers, 7 (valerate excluded) were part of the final 8-item biomarker panel (Fig. 1) that best 
discriminated IBS patients from HC. Also TNF-α was identified as one of the discriminatory markers within the 
final biomarker panel, while the difference between IBS and HC in the univariate analysis was not statistically 
significant (p > 0.05). This supports the advantage of a biomarker panel that includes a combination of markers, 
over the use of single biomarkers for the positive identification of IBS patients in a cohort that also included 
healthy controls.
Calprotectin and IL-12p70 were increased in IBS patients compared to HC, pointing to a low-grade 
pro-inflammatory state in IBS, as has been reported previously for subgroups20–22. Interestingly, IL-1β and IL-6 
were decreased in IBS patients compared to HC. IBS is a chronic GI disorder, and in contrast to IL-12p70, which 
is as pro-inflammatory cytokine associated with chronic inflammatory conditions41,42, IL-1β and IL-6 have 
both pro- and anti-inflammatory properties, but are predominantly involved in the acute-phase immunological 
response43–45. This may imply that the acute immunological response in IBS patients may not be affected. It should 
be taken into account that we have measured baseline cytokine levels and not a stimulated cytokine response (e.g. 
by LPS). Therefore, a presumed role of the measured cytokines in the IBS pathophysiology should be interpreted 
with care. The level of CgA was increased in IBS patients compared to HC, as has been observed previously23, 
and may indicate an altered intestinal neuroendocrine activity in IBS patients. Finally, the antimicrobial peptide 
HBD2, as well as the SCFAs caproate and valerate, were decreased in IBS patients compared to HC. The inter-
pretation with regard to IBS pathophysiology is challenging, since a decreased production as well as increased 
breakdown or degradation could underlie the observed differences. Nevertheless, the observed differences in fecal 
concentrations of these markers between IBS patients and HC are indicative of altered gut microbial activity and/
or host-microbe interaction in IBS patients.
Taken together, we have observed significant but subtle differences between IBS patients and HC for several of 
the tested markers. Separately, in line with our hypothesis, these markers lacked potential for the discrimination 
between groups, but when combined had a high predictive value with a good sensitivity (88.1%) and specificity 
(86.5%). The results for the IBS subtypes were comparable, which indicates that the biomarker panel is useful 
regardless of the IBS subtype. The final 8-item biomarker panel consists of markers related to several gut-health 
domains, such as immunology, intraluminal processes and neuroendocrine activity.
In a recent review, Shah et al. tried to identify studies which evaluated IBS prevalence. Based on the 
meta-analysis, the authors concluded that a positive likelihood ratio of ≥ 5 would make an ideal biomarker for the 
diagnosis of IBS46. In our study, the positive likelihood ratio of the 8-item biomarker panel is 6.5, which indicates 
a moderately high probability of obtaining a positive test in the presence of IBS.
The current findings demonstrate that it is possible to identify the presence of a functional gut disorder (i.e. 
IBS) based on a non-invasive biomarker panel even with only subtle changes per single maker between health and 
disease status. As most clinicians (> 70%) do not solely use the Rome III criteria and frequently rely on additional 
(invasive) investigations to make a positive diagnosis of IBS7, a non-invasive biomarker panel could aid the diag-
nostic process of IBS in clinical practice. The identification of the current ‘multi-gut health domain’ panel of fecal 
and plasma markers is an important step in the development of reliable biomarkers for IBS.
Certain limitations of the present study should be mentioned. We have used a clinical IBS cohort with a 
larger number of IBS patients relative to HC. Furthermore, in daily clinical practice there is a particular need 
for a non-invasive diagnostic test to distinguish between functional and organic GI disorders. Therefore, before 
implementation of the biomarker panel in daily clinical practice, further research is needed to assess the value of 
Plasma biomarkers (median [Q1; Q3]) n = 958
Citrulline (μ mol/l) 41.2 [34.7; 49.1]
IL-1β (μ g/l) 0.11 [0.10; 1.00]
IL-6 (μ g/l) 0.19 [0.18; 0.20]
IL-8 (μ g/l) 1.91 [1.30; 2.77]
IL-10 (μ g/l) 0.89 [0.56; 1.23]
IL-12p70 (μ g/l) 1.14 [0.06; 2.25]
TNF-α (μ g/l) 0.08 [0.07; 0.09]
Fecal biomarkers (median [Q1; Q3])
 Chromogranin A (CgA) (nmol/g) 11.1 [7.2; 23.4]
 Calprotectin (μ g/g) 31.6 [10.5; 60.4]
 Human β -defensin 2 (HBD2) (ng/g) 36.8 [22.5; 62.2]
 SCFA (C2): Acetate (μ mol/g) 27.8 [19.6; 47.1]
 SCFA (C3): Propionate (μ mol/g) 7.8 [5.2; 11.6]
 SCFA (C4): Butyrate (μ mol/g) 7.9 [5.0; 12.5]
 SCFA (C5): Valerate (μ mol/g) 1.4 [1.0; 2.0]
 SCFA (C6): Caproate (μ mol/g) 0.3 [0.1; 0.8]
Table 4.  Levels of biomarkers of the LL DEEP cohort: general population.
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the biomarker panel for the discrimination between IBS and organic GI disorders, such as inflammatory bowel 
disease or coeliac disease, and its potential to monitor symptoms over time.
The current 8-item biomarker panel was identified in a subset of subjects of the Maastricht IBS cohort. 
Although external validation in a second independent clinical IBS cohort is needed, we validated the biomarker 
panel in the pre-assigned independent validation set of IBS patients and controls of the Maastricht IBS cohort. 
These subjects were not used in the biomarker panel discovery step. The LifeLines DEEP cohort was a large pop-
ulation based cohort in which biosamples and symptom scores were collected. This cohort was not included in 
the current study as an external validation cohort, but to test the potency of the biomarker panel to pick up the 
presence of gastro-intestinal symptoms in the general population.
Symptom reduction is the primary goal of therapeutic interventions in IBS. Symptom assessment, mostly by 
retrospective paper surveys, is challenging and is subject to recall bias and fake compliance47. Intervention trials 
in IBS patients using symptom scores as main outcomes are hampered by high placebo response48. The identified 
biomarker panel was found to correlate moderately though significantly (r = 0.59, p < 0.001) with GI symptom 
severity in the IBS cohort. This indicates a possible potential of the biomarker panel to quantify responsiveness to 
treatments in addition to symptom scores, in clinical trials. However, this hypothesis needs to be tested further.
IBS is a highly prevalent disorder among the general population, but difficult to identify in subjects not seek-
ing medical attention. Furthermore, a large part of subjects with IBS symptoms does not seek medical attention 
but try to improve their well-being by self-treatment. The evaluation of potential beneficial effects of interventions 
such as food products, supplementals or life style factors on GI health in the general population is challenging, 
since at group level GI symptom severity is low. Alternatively, a biomarker panel next to GI symptom question-
naires may have added value to quantify improvements by a specific intervention in the general population. Since 
our biomarker set is based on multiple gut health domains and correlated significantly with symptoms in IBS 
patients, we hypothesized that it would also be applicable in the general population. As expected, the majority 
of subjects form the general population reported to have no or hardly any GI symptoms, resulting in low overall 
mean symptom scores. As proof of principle, subjects with a 7-day mean score of 1.5 or higher for abdominal 
pain and discomfort were selected. In this study subgroup, a significant moderate correlation (r = 0.51, p = 0.003) 
between the 8-item biomarker panel and GI symptom scores was observed. This may indicate a potential appli-
cation of the current non-invasive 8-item biomarker panel in research focusing on gut health and possible inter-
ventions thereof in the general population. Furthermore, as the biomarker panel reflects various domains of gut 
health and distinguishes patients with a functional GI disorder from healthy subjects, it may be a first step in the 
development of a biomarker (set) for healthy gut function.
Conclusion
A novel, non-invasive, ‘multi-gut health domain’ biomarker panel, with a high predictive value for the discrimina-
tion between IBS patients and healthy controls, has been identified and validated. Furthermore, a moderate and 
highly significant correlation was observed between the biomarker panel and GI symptom severity in a clinical 
IBS cohort as well as in a general population cohort.
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